EDT broadens its manufacturing focus

As we reported in August, Irish drugmaker Elan is not yet ready to spin off its drug delivery unit. Turns out, the drug delivery unit, EDT, is  broadening its manufacturing offerings. "While we have been 40 years manufacturing products for companies, it has almost exclusively been related to a drug delivery contract into which the parties have entered," spokeswoman Fidelma Callanan tells Outsourcing-pharma. "We want to extend this more to specialised manufacturing which is not necessarily tied to drug delivery contracts." Report

Note: This report was changed from an earlier version in which we said that Elan was moving away from drug delivery. Actually, it is the EDT unit that is broadening its focus. We apologize for the error.

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.